471 related articles for article (PubMed ID: 34480905)
1. The role of amyloids in Alzheimer's and Parkinson's diseases.
Salahuddin P; Fatima MT; Uversky VN; Khan RH; Islam Z; Furkan M
Int J Biol Macromol; 2021 Nov; 190():44-55. PubMed ID: 34480905
[TBL] [Abstract][Full Text] [Related]
2. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
3. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
4. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
Atsmon-Raz Y; Miller Y
ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
[TBL] [Abstract][Full Text] [Related]
5. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
6. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.
Tsigelny IF; Crews L; Desplats P; Shaked GM; Sharikov Y; Mizuno H; Spencer B; Rockenstein E; Trejo M; Platoshyn O; Yuan JX; Masliah E
PLoS One; 2008 Sep; 3(9):e3135. PubMed ID: 18769546
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.
Lam HT; Graber MC; Gentry KA; Bieschke J
Biochemistry; 2016 Feb; 55(4):675-85. PubMed ID: 26799377
[TBL] [Abstract][Full Text] [Related]
12. Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers.
Bisi N; Pinzi L; Rastelli G; Tonali N
Molecules; 2024 Feb; 29(3):. PubMed ID: 38338465
[TBL] [Abstract][Full Text] [Related]
13. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.
Walsh DM; Selkoe DJ
Protein Pept Lett; 2004 Jun; 11(3):213-28. PubMed ID: 15182223
[TBL] [Abstract][Full Text] [Related]
14. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease.
Ganguly G; Chakrabarti S; Chatterjee U; Saso L
Drug Des Devel Ther; 2017; 11():797-810. PubMed ID: 28352155
[TBL] [Abstract][Full Text] [Related]
15. Early mechanisms of amyloid fibril nucleation in model and disease-related proteins.
Morel B; Conejero-Lara F
Biochim Biophys Acta Proteins Proteom; 2019 Nov; 1867(11):140264. PubMed ID: 31437584
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins.
Murphy RM
Biochim Biophys Acta; 2007 Aug; 1768(8):1923-34. PubMed ID: 17292851
[TBL] [Abstract][Full Text] [Related]
17. Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases.
Bigi A; Cascella R; Chiti F; Cecchi C
Bioessays; 2022 Nov; 44(11):e2200086. PubMed ID: 36104212
[TBL] [Abstract][Full Text] [Related]
18. Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.
Nors Perdersen M; Foderà V; Horvath I; van Maarschalkerweerd A; Nørgaard Toft K; Weise C; Almqvist F; Wolf-Watz M; Wittung-Stafshede P; Vestergaard B
Sci Rep; 2015 May; 5():10422. PubMed ID: 26020724
[TBL] [Abstract][Full Text] [Related]
19. A brief overview of amyloids and Alzheimer's disease.
Ow SY; Dunstan DE
Protein Sci; 2014 Oct; 23(10):1315-31. PubMed ID: 25042050
[TBL] [Abstract][Full Text] [Related]
20. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses.
Zhang X; Sun XX; Xue D; Liu DG; Hu XY; Zhao M; Yang SG; Yang Y; Xia YJ; Wang Y; Liu RT
Biochim Biophys Acta; 2011 Dec; 1814(12):1703-12. PubMed ID: 21979582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
